Patents by Inventor Christopher M. Starr

Christopher M. Starr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
    Patent number: 10716862
    Abstract: The present invention provides for compositions and methods for treating, ameliorating or preventing a lysosomal storage disease by administering to a patient suffering front a lysosomal storage disease a P97 conjugated with an enzyme which is capable of transportation into the lysosomes of cells on either sides of the blood brain barrier.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: July 21, 2020
    Assignee: BiOasis Advanced Technologies Inc.
    Inventors: Christopher M. Starr, Todd Zankel
  • USE OF P97 AS AN ENZYME DELIVERY SYSTEM FOR THE DELIVERY OF THERAPEUTIC LYSOSOMAL ENZYMES
    Publication number: 20200188522
    Abstract: The present invention provides for compositions and methods for treating, ameliorating or preventing a lysosomal storage disease by administering to a patient suffering from a lysosomal storage disease a P97 conjugated with an enzyme which is capable of transportation into the lysosomes of cells on either side of the blood brain barrier.
    Type: Application
    Filed: October 18, 2019
    Publication date: June 18, 2020
    Inventors: Christopher M. Starr, Todd Zankel
  • COMPOSITIONS COMPRISING RECEPTOR-ASSOCIATED PROTEIN (RAP) VARIANTS SPECIFIC FOR CR-CONTAINING PROTEINS AND USES THEREOF
    Publication number: 20180118802
    Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes.
    Type: Application
    Filed: December 13, 2017
    Publication date: May 3, 2018
    Inventors: Todd C. Zankel, Christopher M. Starr
  • Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
    Patent number: 9879064
    Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: January 30, 2018
    Assignee: Horizon Orphan LLC
    Inventors: Todd C. Zankel, Christopher M. Starr
  • USE OF P97 AS AN ENZYME DELIVERY SYSTEM FOR THE DELIVERY OF THERAPEUTIC LYSOSOMAL ENZYMES
    Publication number: 20180021445
    Abstract: The present invention provides for compositions and methods for treating, ameliorating or preventing a lysosomal storage disease by administering to a patient suffering front a lysosomal storage disease a P97 conjugated with art enzyme which is capable of transportation into the lysosomes of cells on either sides of the blood brain barrier.
    Type: Application
    Filed: February 28, 2017
    Publication date: January 25, 2018
    Inventors: Christopher M. Starr, Todd Zankel
  • Compositions Comprising Receptor-Associated Protein (RAP) Variants Specific for CR-Containing Proteins and Uses Thereof
    Publication number: 20160024172
    Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes.
    Type: Application
    Filed: June 23, 2015
    Publication date: January 28, 2016
    Inventors: Todd C. Zankel, Christopher M. Starr
  • Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
    Patent number: 9062126
    Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes.
    Type: Grant
    Filed: September 18, 2006
    Date of Patent: June 23, 2015
    Assignee: RAPTOR PHARMACEUTICALS INC.
    Inventors: Todd C. Zankel, Christopher M. Starr
  • Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof
    Patent number: 8877714
    Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes. The invention also relates to antibodies that bind to one or a small subset of CR-containing proteins.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: November 4, 2014
    Assignee: Raptor Pharmaceutical Inc.
    Inventors: Christopher M. Starr, Todd C. Zankel
  • Treatment of liver disorders by administration of RAP conjugates
    Patent number: 8795627
    Abstract: The present invention relates to the use of receptor-associate protein (RAP) and fragments and variants thereof to improve delivery of therapeutic compounds to the liver and provides methods to treat liver disorders and conditions, such as hepatic carcinoma, by administering RAP or RAP variants conjugated to active agents.
    Type: Grant
    Filed: September 18, 2007
    Date of Patent: August 5, 2014
    Assignee: Raptor Pharmaceuticals Inc.
    Inventors: Christopher M. Starr, Todd C. Zankel
  • USE OF P97 AS AN ENZYME DELIVERY SYSTEM FOR THE DELIVERY OF THERAPEUTIC LYSOSOMAL ENZYMES
    Publication number: 20140105880
    Abstract: The present invention provides for compositions and methods for treating, ameliorating or preventing a lysosomal storage disease by administering to a patient suffering from a lysosomal storage disease a P97 conjugated with an enzyme which is capable of transportation into the lysosomes of cells on either sides of the blood brain harrier.
    Type: Application
    Filed: August 16, 2013
    Publication date: April 17, 2014
    Inventors: Christopher M. Starr, Todd Zankel
  • Megalin-based delivery of therapeutic compounds to the brain and other tissues
    Patent number: 8609103
    Abstract: The present invention is directed to a methods and compositions for receptor mediated drug delivery, particularly across the blood-brain barrier.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: December 17, 2013
    Assignee: Raptor Pharmaceuticals Inc.
    Inventors: Todd C. Zankel, Christopher M. Starr
  • Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
    Patent number: 8546319
    Abstract: The present invention provides for compositions and methods for treating, ameliorating or preventing a lysosomal storage disease by administering to a patient suffering from a lysosomal storage disease a P97 conjugated with an enzyme which is capable of transportation into the lysosomes of cells on either sides of the blood brain barrier.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: October 1, 2013
    Assignee: biOasis Advanced Technologies Inc.
    Inventors: Christopher M. Starr, Todd Zankel
  • Cyclic receptor-associated protein (RAP) peptides
    Patent number: 8440629
    Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: May 14, 2013
    Assignee: Raptor Pharmaceuticals Inc.
    Inventors: Christopher M. Starr, Todd C. Zankel
  • TREATMENT OF LIVER DISORDERS BY ADMINISTRATION OF RAP CONJUGATES
    Publication number: 20120251444
    Abstract: The present invention relates to the use of receptor-associate protein (RAP) and fragments and variants thereof to improve delivery of therapeutic compounds to the liver and provides methods to treat liver disorders and conditions, such as hepatic carcinoma, by administering RAP or RAP variants conjugated to active agents.
    Type: Application
    Filed: September 18, 2007
    Publication date: October 4, 2012
    Inventors: Christopher M. Starr, Todd C. Zankel
  • Megalin-Based Delivery of Therapeutic Compounds to the Brain and Other Tissues
    Publication number: 20110142763
    Abstract: The present invention is directed to a methods and compositions for receptor mediated drug delivery, particularly across the blood-brain barrier.
    Type: Application
    Filed: November 8, 2010
    Publication date: June 16, 2011
    Applicant: Raptor Pharmaceuticals Inc.
    Inventors: TODD ZANKEL, CHRISTOPHER M. STARR
  • Use of p97 As An Enzyme Delivery System For The Delivery of Therapeutic Lysosomal Enzymes
    Publication number: 20100303797
    Abstract: The present invention provides for compositions and methods for treating, ameliorating or preventing a lysosomal storage disease by administering to a patient suffering from a lysosomal storage disease a P97 conjugated with an enzyme which is capable of transportation into the lysosomes of cells on either sides of the blood brain barrier.
    Type: Application
    Filed: March 23, 2010
    Publication date: December 2, 2010
    Applicant: BIOASIS TECHNOLOGIES INC.
    Inventors: Christopher M. Starr, Todd Zankel
  • Receptor associated protein (RAP) conjugates
    Patent number: 7829537
    Abstract: The present invention is directed to a methods and compositions for receptor mediated drug delivery, particularly across the blood-brain barrier.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: November 9, 2010
    Assignee: Raptor Pharmaceuticals Inc.
    Inventors: Todd C. Zankel, Christopher M. Starr
  • CYCLIC RECEPTOR-ASSOCIATED PROTEIN (RAP) PEPTIDES
    Publication number: 20100210517
    Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes.
    Type: Application
    Filed: March 21, 2008
    Publication date: August 19, 2010
    Applicant: Raptor Pharmaceutical Inc.
    Inventors: Christopher M. Starr, Todd C. Zankel
  • MEGALIN-BASED DELIVERY OF THERAPEUTIC COMPOUNDS TO THE BRAIN AND OTHER TISSUES
    Publication number: 20100028370
    Abstract: The present invention is directed to a methods and compositions for receptor mediated drug delivery, particularly across the blood-brain barrier.
    Type: Application
    Filed: July 24, 2009
    Publication date: February 4, 2010
    Applicant: RAPTOR PHARMACEUTICAL INC.
    Inventors: TODD ZANKEL, Christopher M. Starr
  • Compositions Comprising Receptor-Associated Protein (RAP) Variants Specific for CR-Containing Proteins and Uses Thereof
    Publication number: 20090281024
    Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes.
    Type: Application
    Filed: September 18, 2006
    Publication date: November 12, 2009
    Applicant: RAPTOR PHARMACEUTICAL INC.
    Inventors: Todd C. Zankel, Christopher M. Starr